Clinical trials: Cancer Unknown Primary
Squamous Cell Carcinomas
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups.
- Trial name
- NCT01706939
- Testing
- Reduced Dose Radiation, Standard Dose Radiation, Carboplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Squamous Cell Carcinoma of the Oropharynx
Evaluation of Tongue Base MucOsectomy & Step sErial Sectioning
Squamous cell carcinoma (SCC) is a cancer that originates from the cells lining the body and can spread into the lymph glands and beyond. Some patients first present with an SCC which has moved to the lymph glands of the neck.
- Trial name
- MOSES (NCT04151134)
- Testing
- Step serial sectioning histological processing
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Head and Neck Squamous Cell Carcinoma
Transoral Robotic Surgery and Tailored Radiotherapy in Unknown Primary and Small Squamous Cell Head and Neck Cancer
The purpose of this study is to evaluate the use of Transoral Robotic Surgery (TORS) to identify small oropharyngeal carcinomas.
- Trial name
- FIND (NCT03281499)
- Testing
- da Vinci Surgical System Model IS4000
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University Health Network, Toronto
Carcinoma of Unknown Primary
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
This study is for patients with a type of cancer called carcinoma of unknown primary site (CUP), meaning that the site of the body where the tumor has originated is not clear.
- Trial name
- NCT00148135
- Testing
- Carboplatin, Gemcitabine, Capecitabine
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Neuroendocrine Carcinoma
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
there is a need for improving chemotherapy regimen for metastatic G3 NEC of GEP and Unknown origin and this goal may be achieved through more "personalized" chemotherapy regimen.the hypothesis is that mFOLFIRINOX regimen could be…
- Trial name
- FOLFIRINEC (NCT04325425)
- Testing
- FOLFOXIRI Protocol, Cisplatin injection
- Where
- 6 sites in France
- Volunteers
- 218 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Cancer
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of aminocamptothecin in treating patients with advanced…
- Trial name
- NCT00003548
- Testing
- aminocamptothecin colloidal dispersion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Cancer, CUP
Living Without Answers - ILLUMINATE CUP
This project aims to improve care, service delivery, and patient experience for people with Cancer of Unknown Primary (CUP) by addressing a critical gap in understanding the lived experiences of patients and carers.
- Conditions
- Cancer, CUP, Cancer Unknown Primary
- Trial name
- ILLUMINATE CUP (NCT07712965)
- Volunteers
- 20 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Cancer
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003867
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Unknown Primary Tumor
Positron Emission Tomography - Computed Tomography (PET-CT) Scan as a Diagnostic Method in Unknown Primary Tumors
Is PET-CT scan better than PET or CT alone in diagnosing primary tumours in patients with unknown primary tumors? Can information obtained with PET-CT replace other clinical and radiological investigations? Is PET/CT…
- Trial name
- NCT00269373
- Testing
- PET-CT
- Where
- Denmark
- Volunteers
- 136 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Melanoma Neoplasms
Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma
the study aims to implement new approaches for the identification of circulating tumor cells and circulating microRNAs, which aim to silence the expression of genes and thus prevent the production of proteins in patients with…
- Trial name
- NCT06863870
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Malignant Melanoma Stage III
Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma
DONIMI is a phase 1b trial testing the combination of domatinostat + nivolumab or nivolumab monotherapy in IFN-gamma signature high patients and of domatinostat + nivolumab or domatinostat + nivolumab + ipilimumab in IFN-gamma…
- Trial name
- DONIMI (NCT04133948)
- Testing
- Domatinostat, Nivolumab, Ipilimumab
- Where
- 2 sites in Australia, Netherlands
- Volunteers
- 44 people
- Sponsor
- The Netherlands Cancer Institute
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Ovarian, Melanoma
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid…
- Conditions
- Ovarian, Melanoma, Renal, Prostate
- Trial name
- NCT00423254
- Testing
- PSMA/PRAME
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mannkind Corporation
Lymph Nodes With Tumor Metastasis
Predicting Tumor Origin Based on Deep Learning of Lymph Node Puncture Cytology
In this study, the investigators aimed to construct a deep learning diagnostic model that uses cytological images to predict primary unknown tumor origins in patients with tumors combined with lymph node metastases.
- Trial name
- NCT06810349
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Carcinoma of Unknown Primary Origin
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00936702
- Testing
- carboplatin, everolimus, paclitaxel
- Where
- 141 sites in United States
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Carcinoma of Unknown Primary, Pain
Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00357630
- Testing
- gemcitabine hydrochloride, quality-of-life assessment
- Where
- 37 sites in United States
- Volunteers
- 52 people
- Sponsor
- Eastern Cooperative Oncology Group
Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body.
- Conditions
- Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma
- Trial name
- NCT02721732
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- M.D. Anderson Cancer Center
Unknown Primary Tumors
Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor
The purpose of this study is to investigate the efficacy of Cisplatin, Paclitaxel, Gemcitabine +/- Avastin (Bevacizumab) in patients with unknown primary tumors.
- Trial name
- NCT00458315
- Testing
- Cisplatin, Paclitaxel, Gemcitabine
- Where
- Denmark
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Spinal Tumor
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
The goal of the first part of this clinical research study is to learn how to deliver more accurate radiation treatment of tumors in the spine.
- Trial name
- NCT01624220
- Testing
- Spinal SBRT (Standard Dose), Spinal SBRT (Higher Dose), Gold Seed Implantation
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center